NEJM: subcutaneous injection of Nemolizumab to treat specific dermatitis itching

Nemolizumab is a subcutaneous injection of human-derived anti-leukal interleukin-31 receptor A monoclonal antibody that can be used to treat itching and inflammation caused by adhesionderitisIn the Phase II study, the researchers examined the therapeutic effect of Nemolizumab on the severity of atopic dermatitispatients from Japan with teryndrine dermatitis were involved during the 16-week trial, with moderate to severe itching and poor response to external drugs, and patients were randomly given nemolizumab (60 mg) or a placebo every 4 weeks until the 16th week, while using an external drugThe main endpoint of the study was the average percentage change from baseline check to week 16 itching assessment (VAS) score (range 0 to 100, with a higher score indicating more itching)Secondary endpoints include changes in the VAS score to week 4, changes in the eczema area and severity index (EASI) score (ranging from 0 to 72, the higher the score is more severe), the dermatology quality of life index score is 4 or less (DLQI; the range 0 to 30, the higher the score, the more severe the description), and the insomnia severity and safety index score is 7 or less (ISI; the higher the score is143 patients were treated with nemolizumab and 72 were given placebo treatmentAt baseline check-ups, the median patient itching VAS score was 75In week 16, the average percentage change in VAS scores in the Nemolizumab group was -42.8 percent and the placebo group was -21.4 percent (difference was -21.5%)The average percentage change in EASI scores in the Nemolizumab group was -45.9% and the placebo group was -33.2%The percentage of patients with a DLQI score of 4 or less in the Nemolizumab group was 40%, the placebo group was 22%, and the percentage of patients with an ISI score of 7 or less in nemolizumab group was 55% and the placebo group was 21%The incidence of injection-related responses in Nemolizumab and placebo groups was 8% and 3%, respectivelystudies have found that subcutaneous injection of Nemolizumab and external drug therapy significantly alleviate the incidence and severity of adhesion dermatitis itching